Latest Dunad Therapeutics News & Updates

See the latest news and media coverage for Dunad Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Dunad Therapeutics

Biotech developing covalent small-molecule therapies for neurodegenerative diseases

dunadtx.com
Headquarters
Cambridge, United States
Founded year
2020
Company type
Private company
Number of employees
15–50

Latest news about Dunad Therapeutics

Company announcements

  • Dunad Therapeutics

    Dunad Therapeutics announces Pearl Huang's induction into AIMBE Fellows

    Pearl Huang, CEO and President, joins the top 2% of medical and biological engineers for her biotechnology innovation and leadership contributions.

  • Dunad Therapeutics

    Dunad Therapeutics welcomes Dr. Stephen Huhn as CMO

    Dr. Huhn brings extensive experience in neurodegenerative disorders, clinical development, and regulatory strategy. He previously served at Stanford University.

  • Dunad Therapeutics

    Dunad Therapeutics nominates DUN’040 as development candidate for ALS

    DUN’040 is a covalent PIKfyve inhibitor mitigating TDP-43 proteinopathy. It achieves high CNS exposure, survival benefit in preclinical studies, and wide therapeutic index. Dunad initiates IND-enabling studies for Phase I.

  • Dunad Therapeutics

    Dunad Therapeutics announces Dr. Antony Burton's presentation

    He will share insights on “Chemoproteomics discovery of a CNS-penetrant covalent inhibitor of PIKfyve” at the 2nd Proteomics-based Drug Discovery Summit in Boston, February 2-4.

Unlock all announcements with a

Media coverage

  • Vancouver Sun

    Dunad Therapeutics Appoints Michael Bonney as Chair of Board of Directors

    CAMBRIDGE, England — Dunad Therapeutics, a biopharmaceutical company developing covalent small molecule therapies with a focus on protein degradation, today announced the appointment of Michael...

  • PharmaTimes

    Novartis signs $1.3bn deal with UK-based Dunad

    Dunad will apply its own platform to generate the novel covalent and targeted protein degrading small molecule drugs Novartis and Cambridge, UK-based Dunad Therapeutics have...

  • PR Newswire

    Dalriada Drug Discovery Celebrates Client Dunad Therapeutics Billion Dollar Collaboration with Novartis

    Dalriada has worked with Dunad since its inception to support the development of its novel small molecule protein degradation modality Since its inception Dunad's R&D...

  • PR Newswire

    Dunad Therapeutics Emerges To Develop Next-generation Small Molecule Therapeutics Based On First Tuneable Targeted Protein Degradation Technology

    CAMBRIDGE, England, March 23, 2021 /PRNewswire/ -- Dunad Therapeutics ("Dunad") emerges today to develop next-generation small molecule therapeutics based on its highly differentiated, tuneable and...

Unlock all articles with a

Never miss news about Dunad Therapeutics

Track Dunad Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Dunad Therapeutics competitors & trending companies

Browse news for competitors to Dunad Therapeutics and other trending companies.